

Tables

	SLE/APS
<i>Age (SD)</i>	46.29 (12.46)
<i>Sex Female (Male)</i>	55 (3)
<i>Manifestations SLE, (n)</i>	Mucocutaneous (54), CNS (7), Renal (17), Haem (3), Joint (57), Serositis (16)
<i>Manifestations APS, (n)</i>	VT (4), PM (2), CVA (2)
<i>aCL, n (mean, SD)</i>	8 (17.91, 42.03)
<i>Anti-β2GPI, n (mean, SD)</i>	3 (14.15, 9.87)
<i>LA positive, n</i>	16
<i>Other autoantibody positivity (n)</i>	aDNA (39), Sm (12), RNP (24), Ro (28), La (3), RF (9),
<i>aFXa, n (mean +/- SD)</i>	38 (21.20, 16.67)
<i>aThr, n (mean +/- SD)</i>	44 (32.43, 26.20)

Supplimentary Table 1. Patient demographics of n=58 clinical associations cohort